Skip to content
OpenCapital
Get started

Galectin Therapeutics GALT Q4 2024 Annual earnings

Reported March 31, 2025 · Before market open

Revenue$36.0KDiluted EPS-$0.19Miss by $0.03
EPS estimate-$0.16

Next report

Aug 13, 2026 (In 4 weeks)
EPS estimate-$0.09

Versus estimates

Revenue

Q4 2024$36.0K

Diluted EPS

Q1 2026-$0.08Miss by $0.02Q4 2025-$0.08Beat by $0.02Q3 2025-$0.13Miss by $0.02Q2 2025-$0.12Beat by $0.04Q1 2025-$0.15Beat by $0.05
Q4 2024-$0.19Miss by $0.03

Ask the moment Galectin Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Galectin Therapeutics report Q4 2024 earnings?
Galectin Therapeutics (GALT) reported Q4 2024 earnings on March 31, 2025 before market open.
What were Galectin Therapeutics's Q4 2024 revenue and EPS?
Galectin Therapeutics reported revenue of $36.0K and diluted EPS of $-0.19 for Q4 2024.
Did Galectin Therapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.16 by $0.03.
Where can I find Galectin Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001140361-25-011169) directly on SEC EDGAR. The filing index links above go to sec.gov.